Revenue Decline: EXEL Industries reported a revenue of €983 million for FY 2024-2025, reflecting a 10.6% decrease primarily due to significant volume reductions in Agricultural Spraying and Sugar Beet Harvesting, indicating a challenging market environment.
EBITDA Drop: The company's recurring EBITDA fell to €67.6 million, representing 6.9% of revenue, down from the previous year, demonstrating limited success in cost structure adjustments amid a downturn in agricultural activities.
Net Income Decrease: Net income amounted to €16.3 million, a substantial drop from €31.2 million last year, primarily impacted by lower current operating income, highlighting profitability pressures in a sluggish market.
Debt Management Improvement: Despite the challenges, EXEL successfully reduced its net financial debt by approximately €30 million to €98.3 million, showcasing improved cash generation capabilities and strengthened financial discipline.
EXEL
$42.85+Infinity%1D
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.33 USD with a low forecast of 30.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
8 Hold
0 Sell
Moderate Buy
Current: 42.000
Low
30.00
Averages
45.33
High
56.00
Current: 42.000
Low
30.00
Averages
45.33
High
56.00
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Exelixis with a Peer Perform rating and no price target. Zanzalintinib is unlikely to fully replenish cabozantinib's potential lost revenues, the analyst tells investors.
Morgan Stanley
Overweight
maintain
$44 -> $45
2025-11-07
Reason
Morgan Stanley
Price Target
$44 -> $45
2025-11-07
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Exelixis to $45 from $44 and keeps an Overweight rating on the shares. Cabo continues to demonstrate sustained demand and the NET launch progresses well with roughly $100M expected in contribution to 2025 net product revenue, the analyst tells investors in a research note. The firm added the company expects to submit the NDA in previously treated mCRC in December 2025, pending the U.S. government re-opening.
UBS
Neutral
maintain
$35 -> $40
2025-11-06
Reason
UBS
Price Target
$35 -> $40
2025-11-06
maintain
Neutral
Reason
UBS raised the firm's price target on Exelixis to $40 from $35 and keeps a Neutral rating on the shares.
Stifel
Stephen Willey
Hold
maintain
$41 -> $43
2025-11-05
Reason
Stifel
Stephen Willey
Price Target
$41 -> $43
2025-11-05
maintain
Hold
Reason
Stifel analyst Stephen Willey raised the firm's price target on Exelixis to $43 from $41 and keeps a Hold rating on the shares following a Q3 earnings announcement and corporate update that the firm says had "no significant surprises.
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
